PDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings Effects, Misses Anticipations By $.09 EPS
PDS Biotechnology (NASDAQ:PDSB – Get Score) introduced its quarterly earnings info on Wednesday. The corporation described ($.32) earnings per share for the quarter, lacking the consensus estimate of ($.23) by ($.09), MarketWatch Earnings studies. Throughout the exact same quarter in the earlier year, the company acquired ($.14) earnings for every share.
NASDAQ PDSB traded up $.73 on Friday, reaching $4.56. 552,690 shares of the inventory traded hands, as opposed to its normal volume of 232,316. PDS Biotechnology has a 12 thirty day period reduced of $3.47 and a 12 thirty day period large of $17.85. The firm’s fifty day simple going regular is $5.66 and its 200 working day uncomplicated shifting typical is $7.26.
Many analysts a short while ago weighed in on the enterprise. Noble Economical reissued a “buy” score and issued a $22.00 rate objective on shares of PDS Biotechnology in a report on Thursday. Zacks Investment Investigate slash PDS Biotechnology from a “hold” rating to a “sell” rating in a investigation report on Friday. StockNews.com upgraded PDS Biotechnology to a “sell” rating in a exploration report on Saturday, April 9th. At last, Alliance International Associates dropped their rate target on PDS Biotechnology from $18.00 to $16.00 in a study report on Friday. Two analysts have rated the stock with a offer rating and six have given a purchase score to the stock. In accordance to MarketBeat.com, the organization presently has an normal score of “Buy” and an typical concentrate on cost of $17.00.
Quite a few institutional investors and hedge money have a short while ago included to or lowered their stakes in PDSB. Renaissance Systems LLC grew its stake in PDS Biotechnology by 49.5% for the duration of the 1st quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s inventory valued at $4,117,000 after getting an further 220,300 shares in the past quarter. Vanguard Group Inc. grew its stake in PDS Biotechnology by 7.8% for the duration of the 1st quarter. Vanguard Team Inc. now owns 1,093,885 shares of the company’s inventory valued at $6,771,000 right after getting an additional 79,025 shares in the final quarter. Dimensional Fund Advisors LP grew its stake in PDS Biotechnology by 99.9% in the course of the 1st quarter. Dimensional Fund Advisors LP now owns 69,628 shares of the company’s stock valued at $431,000 soon after getting an added 34,797 shares in the last quarter. BlackRock Inc. grew its stake in PDS Biotechnology by 1.% during the 1st quarter. BlackRock Inc. now owns 435,604 shares of the company’s stock valued at $2,697,000 after attaining an added 4,199 shares in the final quarter. Eventually, Oppenheimer & Co. Inc. grew its stake in PDS Biotechnology by 78.6% through the 1st quarter. Oppenheimer & Co. Inc. now owns 25,000 shares of the company’s stock valued at $155,000 right after acquiring an more 11,000 shares in the previous quarter. Hedge funds and other institutional buyers possess 20.94% of the company’s inventory.
PDS Biotechnology Corporation Profile (Get Ranking)
PDS Biotechnology Corporation, a scientific-stage biopharmaceutical business, focuses on producing multifunctional cancer immunotherapies. Its direct solution applicant is PDS0101 (HPV16), which is in Stage II scientific demo supplies a initial line therapy for the recurrent/metastatic head and neck most cancers, human papillomavirus related malignancies, and cervical cancer.
See Also
Receive Information & Scores for PDS Biotechnology Day-to-day – Enter your email deal with under to get a concise daily summary of the newest information and analysts’ rankings for PDS Biotechnology and connected corporations with MarketBeat.com’s Cost-free daily email e-newsletter.
